MOUSE ANTI-HUMAN CD3, T-CELL, FITC & CD8, T-CELL(SUPPRESSOR/CYTOTOXIC) RPE

K955909 · Dako Corp. · GKZ · Mar 28, 1996 · Hematology

Device Facts

• Record ID: K955909
• Device Name: MOUSE ANTI-HUMAN CD3, T-CELL, FITC & CD8, T-CELL(SUPPRESSOR/CYTOTOXIC) RPE
• Applicant: Dako Corp.
• Product Code: GKZ · Hematology
• Decision Date: Mar 28, 1996
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.5220
• Device Class: Class 2

Intended Use

For In Vitro Diagnostic Use Mouse Anti-Human T-cell, CD3/FITC, UCHT1 + Mouse Anti-Human T-cell, CD8/RPE, DK25 (DAKO Anti-CD3/FITC and Anti-CD8/RPE) has been developed for use in flow cytometry for the analysis of CD3+ and CD8+ T-cells. This reagent allows simultaneous detection and quantification of CD3+CD8+ cells (CD8 positive T-lymphocytes) in normal and pathological conditions such as immunodeficiency disorders. It is one component of the suggested monoclonal antibody (MAb) combination for routine immunophenotyping of lymphocytes in peripheral blood using flow cytometry.

Device Story

Reagent kit containing purified mouse anti-human CD3 (clone UCHT1) conjugated to FITC and mouse anti-human CD8 (clone DK25) conjugated to RPE; used in clinical laboratories for flow cytometric immunophenotyping of peripheral blood lymphocytes. Input: peripheral blood specimens; RBCs lysed prior to analysis. Operation: antibodies bind specific T-cell surface antigens; flow cytometer detects fluorescence signals to quantify CD3+ and CD8+ T-cell subpopulations. Output: quantitative data on T-cell subsets. Healthcare providers use results to assess immune status in patients with immunodeficiency or other pathological conditions. Benefits: enables simultaneous identification and enumeration of T-cell subsets, facilitating routine clinical immunophenotyping.

Clinical Evidence

Clinical evaluation using peripheral blood samples from healthy adults. Compared combination reagent to individual predicate reagents (K942797, K944253). Results: CD3+ correlation >0.99; CD8+ correlation >0.98. Linearity testing using JM cells showed r=0.999 for both markers. Reproducibility assessed across two flow cytometers at three antigen concentrations. Cross-reactivity tested against RBCs, monocytes, granulocytes, lymphocytes, and platelets.

Technological Characteristics

Reagent composition: purified mouse anti-human CD3 (UCHT1) conjugated to FITC and mouse anti-human CD8 (DK25) conjugated to RPE. Buffer: 0.05M Tris-HCl, pH 7.2, 15 mM NaN3, 0.1M NaCl, 1% carrier protein. Principle: fluorochrome-conjugated antibody staining for flow cytometry. No electronic or software components.

Indications for Use

Indicated for in vitro diagnostic use in flow cytometry for the analysis, detection, and quantification of CD3+ and CD8+ T-lymphocytes in peripheral blood specimens from adults, including those with normal conditions or pathological states such as immunodeficiency disorders.

Regulatory Classification

Identification

An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.

Special Controls

*Classification.* Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”

Predicate Devices

• DAKO Monoclonal Mouse Anti-Human T-cell, CD3/FITC, UCHT1 (K942797)
• DAKO Monoclonal Mouse Anti-Human suppressor/cytotoxic T-cell, CD8/RPE, Clone DK25 (K944253)

Submission Summary (Full Text)

{0}

MAR 28 1995

510(k) Summary

K955909

Submitter: DAKO Corporation
6392 Via Real
Carpinteria, CA 93013
[phone]

Contact: Gretchen M. Murray, Ph.D., Regulatory Affairs Asst. Manager

Date Summary
Prepared: November 27, 1995

Device Name: Mouse Anti-Human T-cell, CD3/FITC, UCHT1 +
Mouse Anti-Human T-cell, CD8/RPE, DK25

Classification: Class II according to 21 CFR 864.5220, on the basis that monoclonal antibodies are accessories for automated differential cell counters.

Panel: This device classification is under the Hematology and Pathology devices panel, Division of Clinical Laboratory Devices.

Product Code: GKZ

Predicate Device(s): DAKO Monoclonal Mouse Anti-Human T-cell, CD3/FITC, UCHT1 (DAKO Code Number F0818, FDA K942797) and
DAKO Monoclonal Mouse Anti-Human suppressor/cytotoxic T-cell, CD8/RPE, Clone DK25 (DAKO Code Number R0806, FDA K944253)

Device Description: Purified mouse anti-human CD3, Clone UCHT1, conjugated with fluorescein isothiocyanate, isomer 1 (FITC) + purified mouse anti-human CD8, Clone DK25, conjugated with R-phycoerythrin, present in 0.05M Tris-HCl buffer, pH 7.2, 15 mM NaN₃, 0.1M NaCl, stabilized with 1% carrier protein

Subpopulations of lymphocytes may be stained with fluorochrome-conjugated antibody and evaluated in peripheral blood specimens when contaminating red blood cells (RBC's) are lysed prior to flow cytometric analysis. A subpopulation of WBC's are selected for assessment based upon cell morphology.

Intended Use: For In Vitro Diagnostic Use

Mouse Anti-Human T-cell, CD3/FITC, UCHT1 + Mouse Anti-Human T-cell, CD8/RPE, DK25 (DAKO Anti-CD3/FITC and Anti-CD8/RPE) has been developed for use in flow cytometry for the analysis of CD3⁺ and CD8⁺ T-cells. This reagent allows simultaneous detection and quantification of CD3⁺CD8⁺ cells (CD8 positive T-lymphocytes) in normal and pathological conditions such as immunodeficiency disorders. It is one component of the suggested monoclonal antibody (MAb) combination for routine immunophenotyping of lymphocytes in peripheral blood using flow cytometry.

Comparison of
Technological
Characteristics

Performance characteristics have been established by clinical evaluation of compared to the individual single reagent predicate devices that quantitatively measure CD3⁺ and CD8⁺ T-cells that have been previously cleared by FDA (DAKO CD3/FITC, Code No. F0818 and DAKO CD8/RPE, Code No. R0806). When flow cytometric tests of peripheral blood samples obtained from apparently healthy adults were completed, correlation of Anti-CD3, UCHT1 with

Nov. 27, 1995

{1}

DAKO Anti-CD3/FITC and Anti-CD8/RPE approached a direct 1 : 1 comparison for measurement of CD3+ cells. Correlation of Anti-CD8, DK25 with DAKO Anti-CD3/FITC and Anti-CD8/RPE approached a direct 1 : 1 comparison for measurement of CD8+ cells. Data for the measurement of CD3+ T-cells by DAKO Anti-CD3/FITC and Anti-CD8/RPE reagent compared to DAKO CD3/FITC gave a correlation greater than 0.99 using the whole blood method for flow cytometry. Data for the measurement of CD8+ T-cells by DAKO Anti-CD3/FITC and Anti-CD8/RPE reagent compared to DAKO CD8/RPE gave a correlation greater than 0.98 using the whole blood method for flow cytometry.

The CD3 antibody clone, UCHT1, was clustered at the First Leukocyte Typing Workshop, Paris, France, 1982. The CD8 antibody clone, DK25, was clustered at the Third Leukocyte Typing Workshop, Oxford, England, 1986, under another clone designation.

Linearity testing of DAKO CD3/FITC using JM cells gave the following linear equation:

$$
y = 0.02 + 0.98x; \ r = 0.999
$$

Linearity testing of DAKO CD8/RPE using JM cells gave the following linear equation:

$$
y = 0.06 + 1.01x; \ r = 0.999
$$

In addition, reproducibility of DAKO reagents using replicates (from peripheral blood) run on two different flow cytometers was measured at three concentrations of each antigen. Cross-reactivity of Anti-CD3/FITC, plus Anti-CD8/RPE with peripheral blood cells (red blood cells, monocytes, granulocytes, lymphocytes, and platelets) was measured.

## Conclusions:

Results of the above testing as well as the information provided by the First and Third Leukocyte Typing Workshops indicate that the DAKO Anti-CD3/FITC plus Anti-CD8/RPE reagent performs as well as DAKO CD3/FITC in the detection and enumeration of CD3⁺ lymphocytes while the DAKO Anti-CD3/FITC plus Anti-CD8/RPE reagent performs as well as DAKO CD8/RPE in the detection and enumeration of CD8⁺ lymphocytes using flow cytometry. Safety of the DAKO Anti-CD3/FITC plus Anti-CD8/RPE reagent and its individual predicate devices is high as all reagents are used for in vitro testing.

NOV. 27, 1995